Topical Erythropoietin Hydrogel Formulation for Diabetic Foot Ulcers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 21, 2016

Primary Completion Date

June 11, 2018

Study Completion Date

June 12, 2018

Conditions
Diabetic Foot Ulcer
Interventions
DRUG

A hydrogel containing erythropoietin

Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.

DRUG

Hydrogel (as a part of SOC)

Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.

Trial Locations (5)

Unknown

HaEmek Medical Center, Afula

Rambam Health Care Campus, Haifa

Edith Wolfson Medical Center, Holon

Galilee Medical Center, Nahariya

Poriya Medical Center (a.k.a. Baruch Padeh Medical Center), Tiberias

All Listed Sponsors
lead

Remedor Biomed Ltd

INDUSTRY

NCT02361931 - Topical Erythropoietin Hydrogel Formulation for Diabetic Foot Ulcers | Biotech Hunter | Biotech Hunter